Affordable Access

Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk

Authors
  • Campa, Daniele
  • McKay, James
  • Sinilnikova, Olga
  • Hüsing, Anika
  • Vogel, Ulla Birgitte
  • Hansen, R. D.
  • Overvad, K.
  • Witt, P. M.
  • Clavel-Chapelon, F.
  • Boutron-Ruault, M. C.
  • Chajes, V.
  • Rohrmann, S.
  • Chang-Claude, J.
  • Boeing, H.
  • Fisher, E.
  • Trichopoulou, A.
  • Trichopoulos, D.
  • Palli, D.
  • Villarini, A.
  • Sacerdote, C.
  • And 25 more
Publication Date
Jan 01, 2009
Source
Online Research Database In Technology
Keywords
License
Unknown
External links

Abstract

Fatty acid synthase (FAS) is the major enzyme of lipogenesis. It catalyzes the NADPH-dependent condensation of acetyl-CoA and malonyl-CoA to produce palmitic acid. Transcription of the FAS gene is controlled synergistically by the transcription factors ChREBP (carbohydrate response element-binding protein), which is induced by glucose, and SREBP-1 (sterol response element-binding protein-1), which is stimulated by insulin through the PI3K/Akt signal transduction pathway. We investigated whether the genetic variability of the genes encoding for ChREBP, SREBP and FAS (respectively, MLXIPL, SREBF1 and FASN) is related to breast cancer risk and body-mass index (BMI) by studying 1,294 breast cancer cases and 2,452 controls from the European Prospective Investigation on Cancer (EPIC). We resequenced the FAS gene and combined information of SNPs found by resequencing and SNPs from public databases. Using a tagging approach and selecting 20 SNPs, we covered all the common genetic variation of these genes. In this study we were not able to find any statistically significant association between the SNPs in the FAS, ChREBP and SREPB-1 genes and an increased risk of breast cancer overall and by subgroups of age, menopausal status, hormone replacement therapy (HRT) use or BMI. On the other hand, we found that two SNPs in FASN were associated with BMI.

Report this publication

Statistics

Seen <100 times